SK Biopharmaceuticals Co Ltd
KRX:326030
SK Biopharmaceuticals Co Ltd
Revenue
SK Biopharmaceuticals Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Revenue
₩547.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Revenue
₩2.1T
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Revenue
₩1.3T
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Revenue
₩1.5T
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Revenue
₩210.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Revenue
₩437.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
SK Biopharmaceuticals Co Ltd
Glance View
SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.
See Also
What is SK Biopharmaceuticals Co Ltd's Revenue?
Revenue
547.6B
KRW
Based on the financial report for Dec 31, 2024, SK Biopharmaceuticals Co Ltd's Revenue amounts to 547.6B KRW.
What is SK Biopharmaceuticals Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
35%
Over the last year, the Revenue growth was 54%. The average annual Revenue growth rates for SK Biopharmaceuticals Co Ltd have been 9% over the past three years , 35% over the past five years .
You don't have any saved screeners yet